Alergia e Imunologia

Células T podem ser a melhor esperança do nosso corpo contra a variante Ômicron.

16 Dez, 2021 | 12:59h

T Cells Might Be Our Bodies’ Best Shot Against Omicron – The Atlantic

Avanço das infecções por SARS-CoV-2 em indivíduos plenamente vacinados: medição, causas e impacto.

10 Dez, 2021 | 11:32h

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact – Nature Reviews Immunology

Comentário no Twitter

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact https://t.co/dd91AkYmu4 pic.twitter.com/1ByzLeTdlh

— Nature Rev Immunol (@NatRevImmunol) December 7, 2021

[Comunicado de imprensa – ainda não publicado] Estudo laboratorial sugere que uma terceira dose (reforço) da vacina da Pfizer–BioNTech pode ser necessária para fornecer uma resposta imunológica adequada à variante Ômicron.

9 Dez, 2021 | 15:35h

Comunicado de imprensa: Pfizer and Biontech provide update on Omicron variant

Comentários:

Omicron likely to weaken COVID vaccine protection – Nature

Pfizer-BioNTech says COVID booster should protect against Omicron – CIDRAP

Expert reaction to press release from Pfizer-BioNTech about omicron and neutralising antibody titres after two and three vaccine doses – Science Media Centre

Covid: Pfizer says booster shot promising against Omicron – BBC

Pfizer-BioNTech Covid-19 shot loses power against Omicron variant, but booster restores protection – STAT

Múltiplos estudos preliminares encontram evasão notável da Ômicron à vacina.

9 Dez, 2021 | 15:32h

Multiple early studies find notable Omicron vaccine evasion – CIDRAP

Conteúdo relacionado: A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

Estudo randomizado | Em crianças de 6 a 11 anos com asma moderada a grave sem controle adequado, a adição de dupilumabe reduziu as exacerbações e melhorou a função pulmonar.

9 Dez, 2021 | 15:28h

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma – New England Journal of Medicine

Comentário: International study supports dupilumab for treatment of moderate-to-severe asthma in children – Vanderbilt University Medical Center

Um primeiro e pequeno estudo sugere que a variante Ômicron é uma ameaça maior à imunidade contra Covid-19 do que outras variantes.

8 Dez, 2021 | 13:20h

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants – STAT

Estudo original: SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection – medRxiv

Comentário do autor no Twitter (fio – clique para saber mais)

We have completed our first experiments on neutralization of Omicron by Pfizer BNT162b2 vaccination elicited immunity

Manuscript available at https://t.co/rGaEB9GdmS

and should be available on medRxiv in the coming days

— Alex Sigal (@sigallab) December 7, 2021

Ver também (fio – clique para saber mais)

New work from AHRI's @sigallab strongly suggests that the SARS-CoV-2 #Omicron variant escapes antibody immunity induced by the Pfizer vaccine, but that considerable immunity is retained in people who were both vaccinated & previously infected. https://t.co/AZWi3qexin pic.twitter.com/3phPFyKEPh

— Africa Health Research Institute (@AHRI_News) December 7, 2021

Além da Ômicron: o que está por vir quanto à evolução viral da COVID.

8 Dez, 2021 | 13:11h

Beyond Omicron: what’s next for COVID’s viral evolution – Nature

Estudo mostra imunogenicidade aumentada com intervalos maiores entre as doses de vacinas de mRNA contra o SARS-CoV-2.

7 Dez, 2021 | 11:47h

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals – JAMA

Comentário no Twitter (fio – clique para saber mais)

1/ Not surprisingly, a longer delay between 1st & 2nd doses of mRNA COVID vaccines (i.e. 6-7 weeks rather than 3-4 weeks) results in better immune responses.https://t.co/XhiU6u0hYb

— Céline Gounder, MD, ScM, FIDSA (@celinegounder) December 3, 2021

Estudo no Reino Unido mostra que 6 diferentes reforços contra COVID-19 são seguros e aumentam a imunidade quando dados depois de 2 doses de vacinas da AstraZeneca ou Pfizer-BioNTech, com variações significativas nas respostas imunes.

6 Dez, 2021 | 16:27h

Comunicado de imprensa: Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with large variations in immune responses, UK trial shows – The Lancet

Estudo original: Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial – The Lancet

Comentários:

Six different COVID-19 boosters induce variable immune response – CIDRAP

Covid booster shots significantly strengthen immunity, trial finds – The Guardian

Expert reaction to COV-BOOST study investigating safety and immunogenicity of seven COVID-19 vaccines as a third dose following two doses of either Oxford-AstraZeneca or Pfizer – Science Media Centre

Comentário no Twitter

NEW—Six different COVID-19 boosters are safe and increase immunity when given after two doses of #AstraZeneca or #Pfizer-BioNTech, with large variations in immune responses, UK trial shows. https://t.co/ktUp1m2Rsb pic.twitter.com/wlwxcLYDm1

— The Lancet (@TheLancet) December 2, 2021

Ômicron está reforçando o debate sobre doses de reforço das vacinas contra COVID – “Os dados têm mostrado, cada vez mais, que as doses de reforço aumentam a proteção – mas a durabilidade, o impacto e a capacidade de anular a nova variante são desconhecidos.”

3 Dez, 2021 | 11:07h

Omicron is supercharging the COVID vaccine booster debate – Nature